Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03019055 | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell | completed | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05270928 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# | completed | Phase 1 | 6 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03328104 | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma(ENCERT) | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01749969 | SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients | completed | Phase 1 | 57 | SanofiINDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03991884 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT02185820 | Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)(CPD) | completed | Phase 1 / Phase 2 | 57 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02204241 | Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 1 / Phase 2 | 36 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01166113 | Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide(PCP) | completed | Phase 1 / Phase 2 | 67 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 11 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT00458653 | Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma | completed | Phase 1 | 45 | Beth Israel Deaconess Medical CenterOTHER | 2 | Jun 22, 2023 | clinicaltrials |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | completed | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02135406 | CART-19 for Multiple Myeloma | completed | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02797964 | A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | completed | Phase 1 / Phase 2 | 107 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03003546 | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | completed | Phase 1 | 30 | Nektar TherapeuticsINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04754100 | agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 13 | MiNK TherapeuticsINDUSTRY | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT02309580 | Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma | completed | Phase 1 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT01925131 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 50 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT02431988 | Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation(COBALT) | completed | Phase 1 | 10 | University College, LondonOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02751255 | Daratumumab in Combination With ATRA(DARA/ATRA) | completed | Phase 1 / Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT03802955 | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | completed | Phase 1 | 62 | Adagene (Suzhou) LimitedINDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT02659943 | T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03242889 | A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03994913 | Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma | completed | Phase 1 / Phase 2 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 117 | AbbVieINDUSTRY | 4 | Apr 10, 2023 | clinicaltrials |
| NCT01040026 | Expanded Natural Killer (NK) Cells for Multiple Myeloma Study | completed | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 85 | Genentech, Inc.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 50 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02278315 | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 31 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03305445 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | completed | Phase 1 | 6 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03836768 | BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | completed | Phase 1 | 20 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04626843 | Intermittent Fasting and CLL/SLL | completed | Phase 1 | 15 | Eleah StringerOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT01768338 | Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma | completed | Phase 1 | 9 | Michael John RobertsonOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02257242 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma(BRiM) | completed | Phase 1 | 11 | Brown UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT00585195 | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer(PROFILE 1001) | completed | Phase 1 | 596 | PfizerINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03357627 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT04152148 | A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients | completed | Phase 1 | 16 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT00806065 | Study of ENMD-2076 in Patients With Multiple Myeloma | completed | Phase 1 | 13 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02658929 | Study of bb2121 in Multiple Myeloma | completed | Phase 1 | 67 | CelgeneINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02342665 | Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL | completed | Phase 1 / Phase 2 | 25 | BayerINDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2023source: clinicaltrials